OBJECTIVE: To assess the cost-utility of first and second-generation antipsychotics for treatment of schizophrenia. METHODS: A five-year Markov model was constructed based on a survey of the records of patients seen in 2006 at a psychosocial care center in the municipality of Florianopolis, Southern Brazil. Costs were evaluated from the perspective of the Sistema Unico de Saúde (SUS - Unified Healthcare System). Utility was measured in quality-adjusted life years obtained in the literature. RESULTS: The Markov model indicated risperidone and haloperidol utilization before olanzapine as the most cost-effective alternatives. CONCLUSIONS: Antipsychotic agents haloperidol and risperidone are more cost-effective than olanzapine. Strategies prioritizing the use of antipsychotics with better cost-effectiveness could optimize resource allocation without necessarily compromising the health of patients treated through the Sistema Unico de Saúde.
OBJECTIVE: To assess the cost-utility of first and second-generation antipsychotics for treatment of schizophrenia. METHODS: A five-year Markov model was constructed based on a survey of the records of patients seen in 2006 at a psychosocial care center in the municipality of Florianopolis, Southern Brazil. Costs were evaluated from the perspective of the Sistema Unico de Saúde (SUS - Unified Healthcare System). Utility was measured in quality-adjusted life years obtained in the literature. RESULTS: The Markov model indicated risperidone and haloperidol utilization before olanzapine as the most cost-effective alternatives. CONCLUSIONS: Antipsychotic agents haloperidol and risperidone are more cost-effective than olanzapine. Strategies prioritizing the use of antipsychotics with better cost-effectiveness could optimize resource allocation without necessarily compromising the health of patients treated through the Sistema Unico de Saúde.
Authors: Gregory Kruse; Bruce J O Wong; Mei Sheng Duh; Patrick Lefebvre; Marie-Hélène Lafeuille; John M Fastenau Journal: Pharmacoeconomics Date: 2015-10 Impact factor: 4.981
Authors: Denise Razzouk; Monica Kayo; Aglaé Sousa; Guilherme Gregorio; Hugo Cogo-Moreira; Andrea Alves Cardoso; Jair de Jesus Mari Journal: PLoS One Date: 2015-04-08 Impact factor: 3.240
Authors: Alfonso González-Valderrama; Cristián Mena; Juan Undurraga; Carlos Gallardo; Pilar Mondaca Journal: Front Psychiatry Date: 2015-04-14 Impact factor: 4.157
Authors: Wallace Breno Barbosa; Juliana de Oliveira Costa; Lívia Lovato Pires de Lemos; Rosângela Maria Gomes; Helian Nunes de Oliveira; Cristina Mariano Ruas; Francisco de Assis Acurcio; Corrado Barbui; Marion Bennie; Brian Godman; Augusto Afonso Guerra Journal: Appl Health Econ Health Policy Date: 2018-10 Impact factor: 2.561